|Mr. John F. Crowley||Chairman & CEO||1.72M||N/A||1967|
|Mr. Bradley L. Campbell||Pres, COO & Director||657.99k||N/A||1976|
|Mr. William D. Baird III||Chief Financial Officer||543.52k||19.43k||1972|
|Ms. Ellen S. Rosenberg||Gen. Counsel & Corp. Sec.||N/A||N/A||1963|
|Dr. Jay A. Barth||Chief Medical Officer||782.29k||N/A||1964|
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2018 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 7; Compensation: 4.